期刊文献+

增生性狼疮性肾炎的综合治疗

下载PDF
导出
摘要 系统性红斑狼疮(SLE)是T和B淋巴细胞功能紊乱累及多系统的全身性免疫疾病,肾脏为常见的受累器官,即狼疮性肾炎(LN)。根据临床表现LN在SLE中约占25%~70%;而病理检查LN约占90%。目前电子显微镜和免疫荧光检查广泛应用,几乎所有SLE均有程度不等的肾脏病变,且肾脏病理改变程度直接影响SLE的预后。
作者 王媛媛
出处 《中国医刊》 CAS 2010年第11期18-20,共3页 Chinese Journal of Medicine
  • 相关文献

参考文献19

  • 1Cameron JS.Lupus Nephritis[J].J Am Soc Nephrol,1999,10:413-424.
  • 2刘俊铎,沈克勤,刘志红,陈惠萍,黎磊石.弥漫增殖型狼疮性肾炎按血管病变为基础的病理分型探讨[J].肾脏病与透析肾移植杂志,1998,7(3):235-242. 被引量:18
  • 3Flanc RS,Roberts MA,Strippoli GF,et al.Treatment for lupus nephritis[DB].Cochrane Database Syst Rev,2004,(1):CD002922.
  • 4Siemasko KF,Chong AS,Williams JW,et al.Regulation of B cell function by the immunosuppressive agent leflunomide[J].Transplantation,1996,61:635-642.
  • 5Kessel A,Toubi E,Leflunomide in systemic lupus erythematosus[J].Harefuah,2002,141:355-357.
  • 6张晓,周华,董光富,石韫珍.来氟米特对狼疮患者树突状细胞作用机制的初探[J].中华内科杂志,2005,44(5):370-373. 被引量:10
  • 7Tam LS,Li IK,Wong CK,et al.Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy:an open label trial[J].Ann Rheum Dis,2006,65(3):417-418.
  • 8Hallegua D,Wallence DJ,Metzger AL,et al.Cyclosporine for lupus menbranous nephritis:Experience with ten patients and review of the literature[J].Lupus,2000,9(4):241-251.
  • 9Houssiau FA,Lefebvre C,Vnden Berghe M,et al.Serum interleukin 10 titers in systemic lupus erythematosus reflect disease acticity[J].Lupus,1995,4:393-395.
  • 10陈强,刘志红,胡伟新,姚小丹,陈惠萍,陈欣,程震,张波,曾彩虹,黎磊石.普乐可复治疗Ⅳ型狼疮性肾炎的前瞻性临床研究[J].肾脏病与透析肾移植杂志,2002,11(4):301-307. 被引量:33

二级参考文献47

  • 1沈克勤,黎磊石,刘志红,张景红.环孢霉素A治疗狼疮性肾炎的临床研究[J].医学研究生学报,1991,4(2):95-98. 被引量:3
  • 2朱彬,周振安,刘子栋,王小平,任万军.霉酚酸酯与环磷酰胺治疗Ⅳ型狼疮性肾炎的疗效比较[J].山东大学学报(医学版),2003,41(6):692-694. 被引量:11
  • 3张丽红,林琼真.狼疮性肾炎的病理分型进展[J].河北医药,2005,27(2):93-93. 被引量:5
  • 4林燕.狼疮性肾炎的诊治进展[J].河北医药,2005,27(2):94-95. 被引量:5
  • 5Contreras G,Roth D,Pardo V,et al.Lupus nephritis:clinical review for practicing nephrologists.Clinical Nephrology,2002,55:95-107.
  • 6Weening JJ,D'Agati VD,Schwartz MM,et al.The classification of glomerulonephritis in systemic lupus erythematosus revisited.Kidney International,2004,65:512-530.
  • 7Kessel A, Toubi E. Leflunomide in systemic lupus erythematosus. Harefuah, 2002,141:355-357.
  • 8Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol, 1999, 162 :2095-2102.
  • 9Siemasko KF, Chong AS, Williams JW, et al. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation, 1996,61:635-642.
  • 10Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol, 2000,18:767-811.

共引文献77

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部